ERBB2 and breast cancer: In HER2-positive breast cancer, lapatinib inhibits the activation of signalling pathways downstream of EGFR and HER2 including MAPK, PI3K-AKT and PLC-γ, leading to apoptosis, decreased cellular proliferation and cell cycle arrest [41].